Letter to Editor: Rattanaumpawan et al. Severe dengue hemorrhagic fever after TAK-003 dengue vaccination: A case report of a potential vaccine-associated adverse reaction

International Journal of Infectious Diseases 2026 Open access

Read full text
Authors: Vianney Tricou, Mayuri Sharma, Yin Xiang Setoh, Martina Rauscher, Phatraporn Assawawongprom, Stephanie Sonnberg, Jill A. Livengood, Olaf Zent, Shibadas Biswal, Walid Kandeil
DOI: 10.1016/j.ijid.2026.108464
Cited by: 1
References: 7

Abstract

We respond to Rattanaumpawan et al. [1], who describe a potential association between a case of severe dengue hemorrhagic fever and TAK-003 (Qdenga). TAK-003 is a live-attenuated tetravalent dengue vaccine based on a dengue virus (DENV)-2 backbone, expressing premembrane (prM) and envelope (E) proteins from all four serotypes [2]. Detection of all four vaccine strains in the patient’s sample is not unexpected for a live-attenuated tetravalent vaccine and reflects postvaccination viraemia. We wish to address the interpretation of these findings.

Fields of Study & Subjects

Mosquito-borne diseases and control Viral Infections and Outbreaks Research Peripheral Neuropathies and Disorders

Publication details

Journal / source
International Journal of Infectious Diseases
Publisher
Elsevier BV
Volume
165
Pages
108464–108464
Publication date
7 February 2026
Language
EN